Vaxcyte Q2 FY26 net loss widens to $284.3 million; R&D expenses climb to $267.9 million

• Vaxcyte posted a Q2 net loss of $284.3 million, widening from $166.6 million a year earlier.
• R&D expense climbed to $267.9 million from $194.2 million on higher PCV development and manufacturing costs, plus OPUS Phase 3 trial spending.
• Cash, cash equivalents and investments rose to $2.51 billion as of June 30, 2026, from $2.44 billion at year-end.
• VAX-31 adult Phase 3 OPUS trials are fully enrolled; OPUS-1 topline safety, tolerability and immunogenicity data are expected in Q4 2026.
• OPUS-2 and OPUS-3 results are expected in H1 2027, supporting a planned BLA submission and potential U.S. commercial launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051605PRIMZONEFULLFEED9804332) on August 05, 2026, and is solely responsible for the information contained therein.